Stock quote - Summary

Amryt Pharma
AMYT: 20.00 0.00 ( 0.00 %) delayed: 16:57PM
Bid price 19.75 High price 0.00
Ask price 20.25 Low price 0.00
Open price 0.00 Spread 2.47%
Prev close 20.00 Volume 580,299

Amryt Pharma - Share price charts

Intraday
Historic - 6 months

Advanced Amryt Pharma charts >

Amryt Pharma - Share price information
Name Amryt Pharma Epic AMYT
Activities Amryt Pharma plc's (formerly Fastnet Equity, formerly Fastnet Oil & Gas plc, formerly Sterling Green Group plc, formerly Hamilton Partners plc) is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments. The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ('bad' cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood. Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis bullosa (EB), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion. Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. ISIN GB00BDD1LS57
Latest Share Price (p) 20.00 Net Gearing (%) 36.73
Market Capitalisation (pm) 54.96 Gross Gearing (%) 49.40
Shares in issue (m) 274.82 Debt Ratio 46.49
P/E Ratio -4.18 Debt-to-Equity Ratio 0.89
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.98
Dividend Yield (%) 0.00 Price to book value 1.66
Dividend Cover 0.00 ROCE (%) -12.63
Earning per share (p) -4.78 EPS Growth (%) 58.47
52-week high / low (p) 28.75 / 16.75 DPS Growth (%) n/a
Amryt Pharma - Broker views
Date Broker Recommendation Price Old target price New target price Notes
14 Nov Beaufort Securities Speculative Buy 65.00 65.00 Reiterates
22 Sep Beaufort Securities Speculative Buy 65.00 65.00 Reiterates
04 Sep Beaufort Securities Speculative Buy 62.00 65.00 Retains
31 Aug Beaufort Securities Speculative Buy 62.00 62.00 Reiterates
26 Jul Beaufort Securities Speculative Buy 62.00 62.00 Reiterates

More Amryt Pharma broker views >

Amryt Pharma - Director deals
Date Director Type Volume / Price Trade value
11 Oct 2017 Markus Ziener Placing 132,955 @ 20.00p £26,591.00
11 Oct 2017 James Culverwell Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 Rory Nealon Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 Joe Wiley Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 Harry Stratford Placing 150,000 @ 20.00p £30,000.00

More Amryt Pharma director deals >

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.